# Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Source: https://onco.cc/trials/nct02861573/  
OnCo record `nct02861573` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Olaparib, Docetaxel in prostate cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) is a phase 1/2 interventional study registered as NCT02861573 by Merck Sharp & Dohme LLC, with 1200 participants planned, started 2016-11-17 and due to reach its primary completion in 2027-10-22. Interventions recorded: Pembrolizumab 200 mg, Olaparib 400 mg, Docetaxel 75 mg/m^2, Prednisone 5 mg, Enzalutamide 160 mg. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02861573
- Phase: 1/2
- Setting: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 1200

## Sources

- ClinicalTrials.gov NCT02861573: https://clinicaltrials.gov/study/NCT02861573

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Olaparib](https://onco.cc/drugs/olaparib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct02861573.json